{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:24Z","timestamp":1792782684050,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Major Projects of Changzhou Health Commission","award":["ZD202119"],"award-info":[{"award-number":["ZD202119"]}]},{"name":"Major Projects of Changzhou Health Commission","award":["ZD202119"],"award-info":[{"award-number":["ZD202119"]}]},{"name":"Major Projects of Changzhou Health Commission","award":["ZD202119"],"award-info":[{"award-number":["ZD202119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma closely related to metabolic disorders is a common and aggressive liver malignancy. The dysregulation of bile acid homeostasis has emerged as a key factor for the development and progression of HCC. We aimed to investigate the relationship between bile acids and HCC diagnosis and progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 744 HBV-related patients (including 396 HCC patients and 348 patients with chronic liver diseases) were enrolled in the current study. The baseline characteristics of patients were collected from electronic medical records, and the levels of bile acid profiles were determined by LC\u2013MS\/MS. Propensity score matching analysis was conducted to reduce the effect of selection bias, and receiver operating characteristic analysis was performed to evaluate the clinical application values of bile acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant differences were observed for most characteristics between the HCC group and the CLD group before PSM analysis. Patients with HCC were older and fatter (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). After adjusting with a 1:1 ratio for age, gender and BMI, 42 HCC patients and 42 non-HCC patients were matched in 2 groups, respectively. The total bile acid level in HCC patients was lower than that in patients with chronic liver diseases before and after PSM analysis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). However, patients with HCC had significantly higher levels of DCA, LCA, and GLCA and lower levels of TCDCA, GUDCA, and TUDCA (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05, respectively). Besides, the TCDCA, TUDCA, GLCA, and GUDCA were significantly correlated with tumor procession. Moreover, the BAs profiles had a superior predictive ability for predicting the development of HCC even in patients with low serum AFP levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with HCC had significantly lower levels of total bile acid, but higher levels of secondary bile acids (DCA, LCA, and GLCA). The levels of primary bile acid (TCDCA) were closely related to tumor size and stage, which indicated that the bile acids were involved in the HCC procession and had important clinical application values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05686-6","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T14:02:15Z","timestamp":1711375335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Alteration of serum bile acid profiles of HBV-related hepatocellular carcinoma identified by LC\u2013MS\/MS"],"prefix":"10.1007","volume":"150","author":[{"given":"Sijia","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-2499","authenticated-orcid":false,"given":"Longgen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"9","key":"5686_CR1","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","volume":"50","author":"JD Amaral","year":"2009","unstructured":"Amaral JD, Viana RJ, Ramalho RM et al (2009) Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 50(9):1721\u20131734. https:\/\/doi.org\/10.1194\/jlr.R900011-JLR200","journal-title":"J Lipid Res"},{"issue":"31","key":"5686_CR2","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.M011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan M, Balasubramanian N, Makishima M et al (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J Biol Chem 276(31):28857\u201328865","journal-title":"J Biol Chem"},{"key":"5686_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112621","author":"MA Barcena-Varela","year":"2021","unstructured":"Barcena-Varela MA (2021) The endless sources of hepatocellular carcinoma heterogeneity. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers13112621","journal-title":"Cancers (basel)"},{"issue":"6","key":"5686_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"5686_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000217","author":"W Chen","year":"2023","unstructured":"Chen W, Ding M, Ji L et al (2023) Bile acids promote the development of HCC by activating inflammasome. Hepatol Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000217","journal-title":"Hepatol Commun"},{"issue":"4","key":"5686_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, Bisanz JE et al (2023) Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol 21(4):236\u2013247. https:\/\/doi.org\/10.1038\/s41579-022-00805-x","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"5686_CR7","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.4254\/wjh.v14.i9.1730","volume":"14","author":"JW Colosimo SandTomlinson","year":"2022","unstructured":"Colosimo SandTomlinson JW (2022) Bile acids as drivers and biomarkers of hepatocellular carcinoma. World J Hepatol 14(9):1730\u20131738. https:\/\/doi.org\/10.4254\/wjh.v14.i9.1730","journal-title":"World J Hepatol"},{"issue":"2","key":"5686_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3760\/cma.j.issn.1007-3418.2020.02.004","volume":"28","author":"Department of Medical Administration N HandHealth Commission of the People's Republic of C","year":"2020","unstructured":"Department of Medical Administration N HandHealth Commission of the People\u2019s Republic of C (2020) Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi 28(2):112\u2013128. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2020.02.004","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"5686_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M et al (2022) Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B 12(2):558\u2013580. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.019","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"5686_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.apsb.2021.12.011","volume":"12","author":"B Guan","year":"2022","unstructured":"Guan B, Tong J, Hao H et al (2022) Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharmaceutica Sinica B 12(5):2129\u20132149. https:\/\/doi.org\/10.1016\/j.apsb.2021.12.011","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"1","key":"5686_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/aps.2014.117","volume":"36","author":"X-f Huang","year":"2015","unstructured":"Huang X-f, W-d Z-y (2015) FXR and liver carcinogenesis. Acta Pharmacol Sin 36(1):37\u201343. https:\/\/doi.org\/10.1038\/aps.2014.117","journal-title":"Acta Pharmacol Sin"},{"key":"5686_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.05.003","author":"DQ Huang","year":"2022","unstructured":"Huang DQ, Singal AG, Kono Y et al (2022) Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2022.05.003","journal-title":"Cell Metab"},{"key":"5686_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S307962","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H et al (2021) The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma 8:435\u2013450. https:\/\/doi.org\/10.2147\/JHC.S307962","journal-title":"J Hepatocell Carcinoma"},{"key":"5686_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","author":"N Kelley","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y et al (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20133328","journal-title":"Int J Mol Sci"},{"key":"5686_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.metabol.2018.01.007","volume":"83","author":"RJ Lamontagne","year":"2018","unstructured":"Lamontagne RJ, CandBouchard CJ, M J. (2018) A broad investigation of the HBV-mediated changes to primary hepatocyte physiology reveals HBV significantly alters metabolic pathways. Metabolism 83:50\u201359. https:\/\/doi.org\/10.1016\/j.metabol.2018.01.007","journal-title":"Metabolism"},{"issue":"4","key":"5686_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","volume":"66","author":"JYL Li TandChiang","year":"2014","unstructured":"Li TandChiang JYL (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66(4):948\u2013983. https:\/\/doi.org\/10.1124\/pr.113.008201","journal-title":"Pharmacol Rev"},{"issue":"3","key":"5686_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"ASF Lok","year":"2009","unstructured":"Lok ASF, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):661\u2013662. https:\/\/doi.org\/10.1002\/hep.23190","journal-title":"Hepatology"},{"key":"5686_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5407","author":"W Luo","year":"2022","unstructured":"Luo W, Guo S, Zhou Y et al (2022) Hepatocellular carcinoma: novel understandings and therapeutic strategies based on bile acids (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2022.5407","journal-title":"Int J Oncol"},{"issue":"10","key":"5686_CR19","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1002\/ijc.33051","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL, Florio AA, Koshiol J et al (2020) Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer 147(10):2743\u20132753. https:\/\/doi.org\/10.1002\/ijc.33051","journal-title":"Int J Cancer"},{"issue":"5","key":"5686_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","volume":"79","author":"T Rezen","year":"2022","unstructured":"Rezen T, Rozman D, Kovacs T et al (2022) The role of bile acids in carcinogenesis. Cell Mol Life Sci 79(5):243. https:\/\/doi.org\/10.1007\/s00018-022-04278-2","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"5686_CR22","doi-asserted-by":"publisher","first-page":"M111 010694","DOI":"10.1074\/mcp.M111.010694","volume":"11","author":"Y Tan","year":"2012","unstructured":"Tan Y, Yin P, Tang L et al (2012) Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteom 11(2):M111 010694. https:\/\/doi.org\/10.1074\/mcp.M111.010694","journal-title":"Mol Cell Proteom"},{"key":"5686_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.829525","volume":"13","author":"JP Thomas","year":"2022","unstructured":"Thomas JP, Modos D, Rushbrook SM et al (2022) The emerging role of bile acids in the pathogenesis of inflammatory bowel disease. Front Immunol 13:829525. https:\/\/doi.org\/10.3389\/fimmu.2022.829525","journal-title":"Front Immunol"},{"issue":"1","key":"5686_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40139-012-0003-6","volume":"1","author":"X Wang","year":"2013","unstructured":"Wang X, Fu X, Van Ness C et al (2013) Bile acid receptors and liver cancer. Curr Pathobiol Rep 1(1):29\u201335","journal-title":"Curr Pathobiol Rep"},{"key":"5686_CR25","doi-asserted-by":"publisher","first-page":"5492931","DOI":"10.1155\/2023\/5492931","volume":"2023","author":"J Wang","year":"2023","unstructured":"Wang J, Xu H, Wang Y et al (2023) Efficacy and safety of drug-eluting bead TACE in the treatment of primary or secondary liver cancer. Can J Gastroenterol Hepatol 2023:5492931. https:\/\/doi.org\/10.1155\/2023\/5492931","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"12","key":"5686_CR26","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1021\/pr300673x","volume":"11","author":"JF Xiao","year":"2012","unstructured":"Xiao JF, Varghese RS, Zhou B et al (2012) LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 11(12):5914\u20135923. https:\/\/doi.org\/10.1021\/pr300673x","journal-title":"J Proteome Res"},{"issue":"8","key":"5686_CR27","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie G, Wang X, Huang F et al (2016) Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 139(8):1764\u20131775. https:\/\/doi.org\/10.1002\/ijc.30219","journal-title":"Int J Cancer"},{"issue":"1","key":"5686_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0038-1676806","volume":"39","author":"YM Yang","year":"2019","unstructured":"Yang YM, Kim S, YandSeki E (2019) Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis 39(1):26\u201342. https:\/\/doi.org\/10.1055\/s-0038-1676806","journal-title":"Semin Liver Dis"},{"issue":"4","key":"5686_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2016.12.018","volume":"66","author":"X Yu","year":"2017","unstructured":"Yu X, Lan P, Hou X et al (2017) HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1\u03b2 production via suppressing the NF-\u03baB pathway and ROS production. J Hepatol 66(4):693\u2013702. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.018","journal-title":"J Hepatol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05686-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T07:11:05Z","timestamp":1712992265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05686-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05686-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author reports no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committees of Changzhou Third Hospital (Approval number: 02A-A20220018). Informed consent forms were read and signed by all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"157"}}